Media Summary: Is it time to rethink the definition of “cure” for stage IV colorectal cancer? In this episode of BackTable Tumor Board, medical ... The full article for this interview is available on Oncology Data Advisor. Check it out here: ... Sara Lonardi, MD, Veneto Institute of Oncology, Padua, Itay, discusses the Phase III

Applying Checkmate 8hw Practical Updates - Detailed Analysis & Overview

Is it time to rethink the definition of “cure” for stage IV colorectal cancer? In this episode of BackTable Tumor Board, medical ... The full article for this interview is available on Oncology Data Advisor. Check it out here: ... Sara Lonardi, MD, Veneto Institute of Oncology, Padua, Itay, discusses the Phase III Heinz-Josef Lenz, MD, FACP, University of Southern California, Los Angeles, CA, discusses expanded analysis results from the ... John Strickler, MD, Duke University, Durham, NC, gives an overview of the Phase III Chiara Cremolini, MD, PhD, University of Pisa, Pisa, Italy, discusses the health-related quality of life (HRQoL) outcomes from the ...

In this episode of the Oncology Brothers podcast, hosts Drs. Rahul and Rohit Gosain are joined by Dr. Nicholas Hornstein, a GI ... Sakti Chakrabarti, MD, University Hospitals Seidman Cancer Center, highlights new data from the BREAKWATER and In this episode of the Oncology Brothers podcast, hosts Drs. Rahul & Rohit Gosain had the pleasure of hosting Dr. Alok Khorana, ... Sara Lonardi, MD, Veneto Institute of Oncology, Padua, Italy, discusses the health-related quality of life (HRQoL) outcomes from ... Heinz-Josef Lenz, MD, FACP, University of Southern California, Los Angeles, CA, highlighted recent data at the 2024 ASCO ... Michael J. Overman, MD, medical oncologist, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The ...

Photo Gallery

Applying CheckMate 8HW: Practical Updates for MSI-High CRC w/ Dr. Cathy Eng | Ep. 75
Clinic Conversation: CheckMate 8HW Study and the Future of Immunotherapy in Colorectal Cancer
CheckMate 8HW: nivolumab & ipilimumab in MSI-H/dMMR metastatic CRC
CheckMate 8HW: expanded analysis of nivolumab & ipilimumab in MSI-H/dMMR mCRC
CheckMate 8HW: nivolumab and ipilimumab in MSI-H/dMMR mCRC
Does Nivolumab and Ipilimumab Combo Outshine Traditional Chemo in Colorectal Cancer?"  CheckMate-8HW
CheckMate 8HW: HRQoL outcomes of nivolumab and ipilimumab in MSI-H/dMMR mCRC
Nivolumab plus Ipilimumab in Microsatellite-Instability–High (MSI-H) Metastatic Colorectal Cancer
Targeted and Immuno-Oncology Advances in mCRC: BREAKWATER, CheckMate 8HW, and CHALLENGE
CheckMate 8HW from GI ASCO 2025 with Nivolumab/Ipilimumab in MSI-H Patients
HRQoL findings from CheckMate 8HW: nivolumab and ipilimumab in MSI-H/dMMR mCRC
KEYNOTE-177 and CheckMate 8HW: promising first-Line immunotherapy for MSI-H mCRC
View Detailed Profile
Applying CheckMate 8HW: Practical Updates for MSI-High CRC w/ Dr. Cathy Eng | Ep. 75

Applying CheckMate 8HW: Practical Updates for MSI-High CRC w/ Dr. Cathy Eng | Ep. 75

Is it time to rethink the definition of “cure” for stage IV colorectal cancer? In this episode of BackTable Tumor Board, medical ...

Clinic Conversation: CheckMate 8HW Study and the Future of Immunotherapy in Colorectal Cancer

Clinic Conversation: CheckMate 8HW Study and the Future of Immunotherapy in Colorectal Cancer

The full article for this interview is available on Oncology Data Advisor. Check it out here: ...

CheckMate 8HW: nivolumab & ipilimumab in MSI-H/dMMR metastatic CRC

CheckMate 8HW: nivolumab & ipilimumab in MSI-H/dMMR metastatic CRC

Sara Lonardi, MD, Veneto Institute of Oncology, Padua, Itay, discusses the Phase III

CheckMate 8HW: expanded analysis of nivolumab & ipilimumab in MSI-H/dMMR mCRC

CheckMate 8HW: expanded analysis of nivolumab & ipilimumab in MSI-H/dMMR mCRC

Heinz-Josef Lenz, MD, FACP, University of Southern California, Los Angeles, CA, discusses expanded analysis results from the ...

CheckMate 8HW: nivolumab and ipilimumab in MSI-H/dMMR mCRC

CheckMate 8HW: nivolumab and ipilimumab in MSI-H/dMMR mCRC

John Strickler, MD, Duke University, Durham, NC, gives an overview of the Phase III

Does Nivolumab and Ipilimumab Combo Outshine Traditional Chemo in Colorectal Cancer?"  CheckMate-8HW

Does Nivolumab and Ipilimumab Combo Outshine Traditional Chemo in Colorectal Cancer?" CheckMate-8HW

Check out this pivotal video on the

CheckMate 8HW: HRQoL outcomes of nivolumab and ipilimumab in MSI-H/dMMR mCRC

CheckMate 8HW: HRQoL outcomes of nivolumab and ipilimumab in MSI-H/dMMR mCRC

Chiara Cremolini, MD, PhD, University of Pisa, Pisa, Italy, discusses the health-related quality of life (HRQoL) outcomes from the ...

Nivolumab plus Ipilimumab in Microsatellite-Instability–High (MSI-H) Metastatic Colorectal Cancer

Nivolumab plus Ipilimumab in Microsatellite-Instability–High (MSI-H) Metastatic Colorectal Cancer

In this episode of the Oncology Brothers podcast, hosts Drs. Rahul and Rohit Gosain are joined by Dr. Nicholas Hornstein, a GI ...

Targeted and Immuno-Oncology Advances in mCRC: BREAKWATER, CheckMate 8HW, and CHALLENGE

Targeted and Immuno-Oncology Advances in mCRC: BREAKWATER, CheckMate 8HW, and CHALLENGE

Sakti Chakrabarti, MD, University Hospitals Seidman Cancer Center, highlights new data from the BREAKWATER and

CheckMate 8HW from GI ASCO 2025 with Nivolumab/Ipilimumab in MSI-H Patients

CheckMate 8HW from GI ASCO 2025 with Nivolumab/Ipilimumab in MSI-H Patients

In this episode of the Oncology Brothers podcast, hosts Drs. Rahul & Rohit Gosain had the pleasure of hosting Dr. Alok Khorana, ...

HRQoL findings from CheckMate 8HW: nivolumab and ipilimumab in MSI-H/dMMR mCRC

HRQoL findings from CheckMate 8HW: nivolumab and ipilimumab in MSI-H/dMMR mCRC

Sara Lonardi, MD, Veneto Institute of Oncology, Padua, Italy, discusses the health-related quality of life (HRQoL) outcomes from ...

KEYNOTE-177 and CheckMate 8HW: promising first-Line immunotherapy for MSI-H mCRC

KEYNOTE-177 and CheckMate 8HW: promising first-Line immunotherapy for MSI-H mCRC

Heinz-Josef Lenz, MD, FACP, University of Southern California, Los Angeles, CA, highlighted recent data at the 2024 ASCO ...

Dr. Overman Discusses Updated Findings of CheckMate-142 in Patients With MSI-H mCRC

Dr. Overman Discusses Updated Findings of CheckMate-142 in Patients With MSI-H mCRC

Michael J. Overman, MD, medical oncologist, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The ...